VEGFA and diabetic retinopathy: The advent of anti-VEGF therapies has represented a major breakthrough in the management of neovascular age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion by targeting vascular endothelial growth factor (VEGF), one of the most potent endogenous inducers of angiogenesis [15,16,17].